IDA Foundation - a not-for-profit supplier of medicines and medical goods - started offering generic oncology products in 2015, because we saw that there was a gap in access to affordable quality products to treat cancer in low- and middle-income countries. The WHO EML and our most requested products formed the starting point to create our range. We combined this input with our knowledge of incidence and cancer types in LMICs (mainly focusing on sub-Saharan Africa) with a potentially high cure rate. We also considered cancer types that are often associated with HIV-positive patients.
All our products go through a stringent quality assurance process and per our QA policy, we continuously monitor the quality of all products. Moreover, since NCDs are not yet part of WHOs PQ programme, our Quality assurance model will be important in making sure that patients only get quality assured products.
We welcome feedback from oncologists in low- and middle-income countries on our product range, selection of priority cancers or any other feedback you may have. We are committed to make oncology and palliative care products accessible for those in resource-poor settings, but we recognize that we need the involvement of clinicians and practitioners in the field if our efforts are to have impact. For an overview of our current product range, see: http://bit.ly/2rLjIml or www.idafoundation.org/oncology for an overview of our current activities.
Contact our oncology project manager Ms. Marieke Korsten with your feedback or for an overview of our most updated prices (email@example.com).